Substituted 4-azatricyclo(22.3.1.04,9)octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them

Claim 2

A compound of formula I ##STR4## wherein either R 1 is hydroxy, R 2 is allyl or n-propyl and there is a single bond between the carbon atoms numbered 14 and 15 R 1 is missing, R 2 is allyl and there is a double bond between the carbon atoms numbered 14 and 15.

Claim 3

The compound according to claim 1 wherein R 1 is hydroxy, R 2 is allyl and there is a single bond between the carbon atoms numbered 14 and 15.

Claim 4

The compounds according to claim 1 wherein either R 1 is hydroxy, R 2 is n-propyl and there is a single bond between the carbon atoms numbered 14 and 15 or R 1 is missing, R 2 is allyl and there is a double bond between the carbon atoms numbered 14 and 15.

Claim 5

A process for the preparation of the compound of formula I wherein R 1 is hydroxy, R 2 is n-propyl and there is a single bond between the carbon atoms numbered 14 and 15 which comprises hydrogenating the corresponding compound of formula I wherein R 2 is allyl.

Claim 6

A process for the preparation of the compound of formula I wherein R 1 is hydroxy, R 2 is n-propyl and there is a single bond between the carbon atoms numbered 14 and 15 which comprises hydrogenating the corresponding compound of formula I wherein R 2 is allyl.

Claim 7

A pharmaceutical composition containing a compound according to claim 1 together with a pharmaceutically acceptable carrier or diluent.

Claim 8

A method for the prevention or treatment of conditions requiring immunosuppression or of inflammatory conditions, such as (a) the prevention and treatment of resistance in situations oi organ or tissue transplantation e.g. of heart, kidney, liver, bone marrow and skin, graft-versus-host disease, such as following bone marrow grafts, autoimmune diseases such as rheumatoid arthritis, systemic Lupus erythematosus, Hashimoto's thyroidis, multiple sclerosis, Myasthenia gravis, diabetes type I and uveitis, cutaneous manifestations of immunologically-mediated illnesses, such as Alopecia areata, and (b) the treatment of inflammatory and hyperproliferative skin diseases, such as psoriasis, atopical dermatitis, contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Lupus erythematosus and acne, comprising administering a therapeutically effective amount of a compound according to claim 1 together with a pharmaceutically acceptable carrier or diluent to a subject in need of such treatment.

Claim 9

A method of treatment of immune-mediated conditions of the eye, such as: auto-immune diseases, e.g. uveitis, keratoplasty or chronic keratitis; allergic conditions, e.g. vernal conjunctivitis; inflammatory conditions or corneal transplants, which comprises topically administering to the eye surface a therapeutically effective amount of a compound according to claim 1 in a pharmaceutically acceptable ophthalmic vehicle.

Claim 10

A process for the preparation of a compound of claim 1 wherein R 1 is hydroxy or is missing and R 2 is allyl, which comprises cultivating an appropriate Streptomyces strain such as Streptomyces tsukubaensis No. 9993 until a sufficient amount of the compound is produced, and isolating the compound from the resulting culture.

Claim 11

A process for the preparation of a compound of claim 1 wherein R 1 is missing and R 2 is allyl, which comprises dehydrating the corresponding compound of claim 1 in which R 1 is hydroxy and isolating the compound.